Sunday, May 27

OC-01.01
GENOMIC AND FUNCTIONAL ANALYSIS OF AMPLIFICATION IN HIGH-GRADE SEROUS AND ENDOMETRIOID OVARIAN CANCER IDENTIFIES NOVEL ONCOGENIC DEPENDENCIES THAT MAY BE TARGETED IN THE TREATMENT OF ADVANCED TUMOURS
Sally Davis ¹; Kaylene Simpson ²; Ian Campbell ¹; Kylie Gorringe ^{1 1}Peter MacCallum Cancer Centre; ²Victorian Centre for Functional Genomics; East Melbourne, Victoria, Australia

OC-01.02
MUTATIONAL PROFILING OF OVARIAN AND ENDOMETRIAL CARCINOMAS REVEALS DISTINCT ALTERATIONS TO IMPROVE CLASSIFICATION
Melissa K. McConechy ¹; Kimberly Wiegand ¹; Jiarui Ding ²; Martin Hirst ³; Sohrab Shah ²; Cheng-Han Lee ⁴; Blake C. Gilks ⁴; Paul Goodfellow ⁵; David G. Huntsman ^1
1University of British Columbia, BC Cancer Agency, Vancouver, BC, Canada; ²University of British Columbia, BC Cancer Research Centre, Vancouver, BC, Canada; ³University of British Columbia, CHiBi, Vancouver, BC, Canada; ⁴University of British Columbia, Vancouver General Hospital, Vancouver, BC, Canada; ⁵Washington University, St. Louis, MO, United States

OC-01.03
SPECIFIC RETINOBLASTOMA (RB) PATHWAY ALTERATIONS DEFINE CLINICAL OUTCOME IN HIGH GRADE SEROUS CARCINOMA (HGSC)
Anca Milea ¹; Sophia George ²; Hal Berman ³; Mona Gauthier ⁴; Patricia Shaw ^5
1UHN, University of Toronto, Department of Laboratory Medicine and Pathobiology; ²UHN, The Campbell Family Institute of Breast Cancer Research; ³UHN, The Campbell Family Institute of Breast Cancer Research, Department of Laboratory Medicine and Pathobiology; ⁴The Campbell Family Institute of Breast Cancer Research, Department of Medical Biophysics; ⁵UHN, Department of Laboratory Medicine and Pathobiology; Toronto, ON, Canada

OC-01.04
MOLECULAR PROFILING OF PRIMARY MUCINOUS TUMOURS OF THE OVARY
Sally Hunter ¹; Georgie Ryland ²; Maria Doyle ²; Simone Rowley ²; Michael Christie ³; Kylie Gorringe ²; Ian Campbell ^2
1Peter MacCallum Cancer Centre; ²Peter MacCallum Cancer Centre; ³Ludwig Institute of Cancer Research; Melbourne, Victoria, Australia

OC-01.05
ABSENCE OF ARID1A-ASSOCIATED PROTEIN EXPRESSION (BAF250) IS ASSOCIATED WITH INCREASED PAKT PHOSPHORYLATION INDEPENDENT OF PIK3CA MUTATION STATUS IN CLEAR CELL AND ENDOMETRIOID OVARIAN CANCERS
Mark Carey ¹; Kim Wiegand ²; Blake Gilks ³; Steve Kalloger ²; Yiling Lu ⁴; Sarah Finlayson ¹; Katherine Stemke-Hale ⁴; Bryan Hennessy ⁵; Gordon Mills ⁴; David Huntsman ^6
1Vancouver Coastal Health and BC Cancer Agency, Vancouver, BC, Canada; ²BC Cancer Agency, Vancouver, BC, Canada; ³Vancouver Coastal Health, Vancouver, BC, Canada; ⁴MD Anderson Cancer Center, Houston, TX, United States; ⁵Beaumont Hospital, Dublin, Ireland; ⁶BC Cancer Agency, Vancouver, BC, Canada

OC-01.06
REACTOME – LINKING PATHWAYS, NETWORKS AND CANCER
Robin Haw ¹; Marija Orlic-Milacic ¹; Karen Rothfels ¹; Guanming Wu ¹; Reactome Team ¹; Henning Hermjakob ²; Peter D'Eustachio ³; Lincoln Stein ^1
1OICR, Toronto, ON, Canada; ²EBI, Hinxton, United Kingdom; ³NYUMC, New York, NY, United States

OC-01.07
EXPRESSION OF VGLL3 IS ASSOCIATED WITH A TUMOUR SUPPRESSOR PHENOTYPE IN EPITHELIAL OVARIAN CANCER
Karen Gambaro ¹; Michael C. J. Quinn ²; Paulina Wojnarowicz ³; Manon de Ladurantaye ²; Kim Leclerc Désaulniers ²; Véronique Barres ²; Diane M. Provencher ⁴; Anne-Marie Mes-Masson ⁵; Mario Chevrette ⁶; Patricia N. Tonin ^7
1Department of Human Genetics, McGill University, Montreal, QC, Canada; ²Centre de recherche du Centre hospitalier de l’Université de Montréal / Institut du cancer de Montréal, Montreal, QC, Canada; ³Department of Human Genetics, McGill University, Montreal, QC, Canada; ⁴Centre de recherche du Centre hospitalier de l’Université de Montréal /Division de gynécologie oncologique, Montreal, QC, Canada; ⁵Centre de recherche du Centre hospitalier de l’Université de Montréal / Institut du cancer de Montréal/Department of Medicine, Montreal, QC, Canada; ⁶The Research Institute of McGill University Health Centre/Department of Surgery, Urology Division, McGill University, Montreal, QC, Canada; ⁷Department of Human Genetics and Medicine, McGill University/The Research Institute of McGill University Health Centre, Montreal, QC, Canada

P.01
BTN3A2 EXPRESSION IN EPITHELIAL OVARIAN CANCER IS ASSOCIATED WITH HIGHER TUMOR INFILTRATING T CELLS AND A BETTER PROGNOSIS
Cécile Le Page ; Alexandre Marineau ; Patrick Bonza ; Kurosh Rahimi ; Louis Cyr ; Jason Madore ; Nathalie Delvoye ; Anne-Marie Mes-Masson ; Diane Provencher ; Jean-Francois Cailhier
ICM/CR-CHUM, Montreal, QC, Canada

P.04
CYTOKINE PROFILING OF HUMAN EPITHELIAL OVARIAN CANCER ASCITES
Isabelle Matte ¹; Denis Lane ¹; Claude Laplante ²; Claudine Rancourt ¹; Alain Piché ^1
1Université de Sherbrooke; ²Centre Hospitalier Universitaire de Sherbrooke; Sherbrooke, QC, Canada

P.07
EXPRESSION AND LOCALIZATION OF PROSTATE APOPTOSIS RESPONSE-4 (PAR-4) DURING OVARIAN TUMOR PROGRESSION
Parvesh Chaudhry ; Mohan Singh ; Valerie Leblanc ; Sophie Parent ; Eric Asselin
Université du Québec à Trois-Rivières, Trois-Rivieres, QC, Canada

P.10
GENE EXPRESSION PROFILING OF HUMAN MESOTHELIAL CELLS AFTER OVARIAN CANCER ASCITES TREATMENT
Alain Piché ¹; Isabelle Matte ¹; Claudine Rancourt ¹; Dimcho Bachvarov ^2
1Université de Sherbrooke, Sherbrooke, QC, Canada; ²Université Laval, Quebec, QC, Canada

P.13
MUTATION ANALYSIS OF CELL LINES DERIVED FROM MATCHED PRIMARY AND RECURRENT EPITHELIAL OVARIAN CANCERS USING NEXT GENERATION SEQUENCING TECHNOLOGY, WITH A FOCUS ON CELL CYCLE RELATED GENES
Guergana Tchakarska ¹; Michael Quinn ¹; Sohrab Shah ²; Ali Bashashati ²; Karey Shumansky ²; Suzanna Arcand ³; Diane Provencher ⁴; Patricia Tonin ⁵; David Huntsman ²; Anne-Marie Mes-Masson ^6
1Institut du Cancer de Montréal, CRCHUM, Montreal, QC, Canada; ²Molecular Oncology, BC Cancer Agency, Vancouver, BC, Canada; ³The Research Institute of the McGill University Health Centre, Montreal, QC, Canada; ⁴Département d’Obstétrique et Gynecologie, Division of Gynecologic Oncology, Université de Montréal, Montreal, QC, Canada; ⁵Department of Human Genetics, McGill University, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada; ⁶Institut du Cancer de Montréal, CRCHUM, Département de Médicine, Université de Montréal, Montreal, QC, Canada

P.16
COMPARISON OF NORMAL REFERENCE CONTROLS USED IN TRANSCRIPTOME ANALYSES OF HIGH GRADE SEROUS OVARIAN TUMOURS
Ashley H. Birch ¹; Diane M. Provencher ²; Anne-Marie Mes-Masson ³; Patricia N. Tonin ^4
1Department of Human Genetics, McGill University; ²Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Institut du cancer de Montréal; ³Division of Gynecologic Oncology and Department of Medicine, Université de Montréal; ⁴Deparments of Human Genetics and of Medicine, McGill University, The Research Institute of the MUHC; Montreal, QC, Canada

P.19
EMPIRICAL CHEMOSENSITIVITY TESTING USING A MICROFLUIDICS-BASED MULTIPLEX PLATFORM
Tamal Das ¹; Liliane Meunier ²; Thomas Gervais ³; Laurent Barbe ⁴; Olivier Guenat ⁵; Diane Provencher ⁶; Anne-Marie Mes-Masson ^7
1Institut du cancer de Montréal, CRCHUM; Department of Engineering Physics, École Polytechnique de Montréal, Montreal, QC, Canada; ²Institut du cancer de Montréal, CRCHUM, Montreal, QC, Canada; ³Department of Engineering Physics, École Polytechnique de Montréal, Montreal, QC, Canada; ⁴Centre Suisse d'électronique et de microtechnique, Newchâtel, Switzerland; ⁵ARTORG Center, Medical Faculty, University of Berne, Berne, Switzerland; ⁶Institut du cancer de Montréal, CRCHUM; Division of Gynecologic Oncology, Université de Montréal, Montreal, QC, Canada; ⁷Institut du cancer de Montréal, CRCHUM; Département de médecine, Université de Montréal, Montreal, QC, Canada

P.22
MODEL SYSTEMS FOR CANCER AND CONTEXTUAL-GENOMIC RESEARCH: CLEAR CELL CARCINOMA OF THE OVARY
Michael Anglesio ¹; Steven Kalloger ²; Karey Schumansky ³; Nataliya Melnyk ¹; Christine Chow ²; Clara Salamanca ¹; Janine Senz ¹; Winnie Yang ⁴; Sohrab Shah ¹; David Huntsman ^5
1Department of Pathology and Lab Medicine, UBC; ²GPEC lab Department of Pathology of VGH and UBC; ³British Columbia Cancer Research Centre, BCCA; ⁴CTAG, BC Cancer Agency; ⁵CTAG, BCCA; and Department of Pathology and Lab Medicine, UBC; Vancouver, BC, Canada

P.25
IDENTIFYING KEY GENES MEDIATING THE TUMOUR-PROMOTING ACTIONS OF ESTROGEN IN OVARIAN CANCER
Kendra Hodgkinson ¹; Laura Laviolette ¹; Carolina Perez-Iratxeta ²; Barbara Vanderhyden ^1
1Cellular and Molecular Medicine, University of Ottawa; Ottawa Hospital Research Institute; ²Ontario Genomics Innovation Centre, Ottawa Hospital Research Institute; Ottawa, ON, Canada

P.28
GENOME-WIDE DNA METHYLATION PROFILING OF CPG ISLANDS IDENTIFIES ACTIVITY-REGULATED CYTOSKELETON-ASSOCIATED PROTEIN (ARC) AS A NOVEL HYPOMETHYLATION TARGET IN OVARIAN CANCER
Jean-François Pelletier ¹; Mamadou Keita ¹; Éric Paquet ²; Magdalena Bachvarova ²; Marie Plante ³; Jean Grégoire ³; Marie-Claude Renaud ³; Chantale Morin ⁴; Dimcho Bachvarov ^5
1Department of Molecular Medicine, Laval University, Lévis, QC, Canada; ²Cancer Research Centre, Hôpital L’Hôtel-Dieu de Québec, Quebec, QC, Canada; ³Department of Obstetrics and Gynecology, Laval University, Quebec, QC, Canada; ⁴Department of Pathology, Laval University, Quebec, QC, Canada; ⁵Department of Molecular Medicine, Laval University, Quebec, QC, Canada

P.31
DIFFERENTIAL EXPRESSION OF STEROID HORMONE RECEPTORS IN FALLOPIAN TUBES AND IN OVARIAN SURFACE EPITHELIUM FROM MEXICAN WOMEN
Veronica Diaz-Hernandez ¹; Delia Perez-Montiel ²; Martin Cadena-Sandoval ¹; Maria Jose Gomora ¹; Flavia Morales Vasquez ²; Enrique Pedernera ¹; Maria del Carmen Mendez ^1
1Universidad Nacional Autonoma De Mexico, Mexico; ²Instituto Nacional de Cancerología, Mexico

P.34
BREAKPOINT ANALYSIS OF 8 HIGH-GRADE SEROUS OVARIAN CARCINOMAS INDICATES THAT CHROMOSOME 19 TENDS TO HAVE MORE BREAKS THAN EXPECTED
Celia M.T. Greenwood ¹; Kathleen Klein Oros ²; Suzanna L. Arcand ³; Diane Provencher ⁴; Anne-Marie Mes-Masson ⁵; Patricia N. Tonin ^6
1Lady Davis Institute for Medical Research, Department of Oncology, McGill University; ²Lady Davis Institute for Medical Research; ³The Research Institute of the McGill University Health Centre; ⁴Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Institut du cancer de Montréal; ⁵Centre de recherche du Centre hospitalier de l’Université de Montréal, Institut du cancer de Montréal; ⁶The Research Institute of the McGill University Health Centre, Departments of Medicine and Human Genetics, McGill University; Montreal, QC, Canada

P.37
VEPH1 IS A NOVEL REGULATOR OF CANONICAL TGF-BETA SIGNALING IN OVARIAN CANCER CELLS
Premalatha Shathasivam ¹; Alexandra Kollara ¹; Carl Virtanen ²; Jeff Wrana ¹; Theodore Brown ^1
1Samuel Lunenfeld Research Institute, Mount Sinai Hospital; University of Toronto; ²OCI Microarray Centre; Toronto, ON, Canada

P.40
IDENTIFICATION OF MEDIATORS IMPLICATED IN THE METASTATIC PROGRESSION OF OVARIAN CANCER TO PERITONEAL MESOTHELIUM USING HIGH-THROUGHPUT PROTEOMICS
Natasha Musrap ¹; George S. Karagiannis ¹; Ihor Batruch ²; Chris Smith ²; Eleftherios P. Diamandis ^2
1University of Toronto; ²Mount Sinai Hospital; Toronto, ON, Canada

P.43
INTEGRATING HIGH-THROUGHPUT TECHNOLOGIES FOR THE IDENTIFICATION AND VALIDATION OF OVARIAN CANCER BIOMARKERS
Felix Leung ¹; Apostolos Dimitromanolakis ²; Eleftherios P. Diamandis ¹; Vathany Kulasingam ^1
1Department of Laboratory Medicine and Pathobiology, University of Toronto; ²Samuel Lunenfeld Research Institute and Department of Pathology and Laboratory Medicine, Mount Sinai Hospital; Toronto, ON, Canada

P.46
MECHANISMS OF KLK6 EXPRESSION AND BIOMARKER DISCOVERY IN OVARIAN CARCINOMAS: AN INTEGRATED GENOMIC, MIRNA AND PROTEOMIC PROFILING APPROACH
Jane Bayani ¹; Uros Kuzmanov ¹; Ihor Batruch ²; Christopher Smith ²; Punit Saraon ¹; William Fung ¹; Jeremy A Squire ³; Eleftherios P Diamandis ^4
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; ²University Health Network, Toronto, ON, Canada; ³Department of Laboratory Medicine and Pathobiology, Queen’s University, Kingston, ON, Canada; ⁴Mount Sinai Hospital and University Health Network, Toronto, ON, Canada

P.49
GLOBAL PROFILING OF DNA METHYLATION IDENTIFIES UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 3 (GALNT3) AS A NOVEL HYPOMETHYLATION TARGET IN OVARIAN CANCER
Zhiqiang Wang ¹; Mamadou Keita ¹; Eric Paquet ²; Magdalena Bachvarova ²; Marie Plante ³; Jean Gregoire ³; Marie-Claude Renaud ³; Chantale Morin ⁴; Dimcho Bachvarov ^1
1Department of Experimental Medicine, Laval University; ²Cancer Research Centre, Hôpital L’Hôtel-Dieu de Québec, Centre Hospitalier Universitaire de Québec (CHUQ); ³Department of Obstetrics and Gynecology, Laval University; ⁴Department of Pathology, Laval University; Quebec, QC, Canada

P.52
IN SILICO CANCER DRUG DISCOVERY: CANDIDATE THERAPEUTICS FOR OVARIAN CANCER FROM AN INTEGRATIVE META-ANALYSIS OF CANCER GENE SIGNATURES AND HIGH-THROUGHPUT DRUG RESPONSE DATA
Josh Griesman ; Kristen Fortney ; Igor Jurisica
Ontario Cancer Institute, Toronto, ON, Canada

P.54
A CANDIDATE GENE SHORT LIST FOR A GRANULOSA CELL TUMOUR SUSCEPTIBILITY GENE (GCT1) IN A SPONTANEOUS MOUSE MODEL OF EARLY-ONSET TUMOURIGENESIS
Kerri Smith ¹; Sarah Halfyard ¹; Edward Yaskowiak ¹; Wesley Beamer ²; Ann Dorward ^1
1Memorial University, St. John's, NL, Canada; ²The Jackson Laboratory, Bar Harbor, ME, United States